Medtronic plc（MDT）の決算・業績分析
Medtronic plcの2025年有価証券報告書をAI分析。売上高$33.5B(+3.6%)。営業利益$6.0B。Health Care。
目次
Medtronic plcの2025年度 業績サマリー
Medtronic plc（証券コード: MDT）の2025年度決算・業績分析。売上高は$33.5B（前年比+3.6%）。営業利益は$6.0B（前年比+15.8%）。純利益は$4.7B（前年比+26.8%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Medtronic plcの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 5.2% YoY to $31.7B (XBRL), driven by strong operating income (+28.3% YoY to $5.8B) and net income (+39.7% YoY to $5.0B) (XBRL).
- Operating margin expanded to 18.1% (XBRL), with net margin at 15.9% (XBRL), reflecting improved cost efficiency and pricing power.
- Free cash flow reached $6.0B (XBRL), with $3.4B in dividends and $2.5B in share repurchases (XBRL), highlighting strong shareholder returns.
Medtronic plcの売上高変化の要因
- •Revenue increased 5.2% YoY to $31.7B (XBRL), with historical growth showing a 5-year CAGR of +0.8% (XBRL). Operating income rose 28.3% YoY to $5.8B (XBRL), outpacing the 5-year CAGR of -3.7% (XBRL) for operating income. Net income surged 39.7% YoY to $5.0B (XBRL), with a 5-year CAGR of +3.9% (XBRL). Growth drivers include innovation in medical devices, strong financial health (56.6% equity ratio) (XBRL), and strategic focus on high-margin segments.
Medtronic plcの営業利益変化の要因
- •Operating margin improved to 18.1% (XBRL), while net margin reached 15.9% (XBRL). EBITDA of $8.5B (26.7% of revenue) (XBRL) reflects strong cost control and operational efficiency. Net income grew 39.7% YoY (XBRL), with a 5-year CAGR of +3.9% (XBRL), outperforming operating income's 5-year CAGR of -3.7% (XBRL).
Medtronic plcの事業リスクと対応
Intense global competition from diverse companies and alternative therapies (10-K).
Reliance on product innovation, quality, and regulatory compliance (10-K).
Supply chain disruptions due to complex manufacturing and global component shortages (10-K).
Regulatory challenges with AI adoption and data security risks (10-K).
Pressure from managed care, reimbursement rates, and pricing competition (10-K).
Geopolitical risks, including national tender pricing in China (10-K).
Medtronic plcの今後の見通し・業績予想
Medtronic plcの事業内容
Medtronic plc is a global healthcare technology company that generates revenue through the sale of medical devices and services, including implantable cardiac devices, ablation systems, and diabetes management solutions (10-K). The company operates four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit (10-K). Key competitive advantages include a robust R&D pipeline ($2.7B in R&D expenses) (XBRL), innovative technologies (e.g., AI, remote monitoring), and a diversified product portfolio (10-K). The company serves healthcare systems, physicians, clinicians, and patients across 150+ countries, with no significant customer concentration (10-K).
Medtronic plcのAI業績分析レポート（2024年度）
Medtronic plc (MDT) Annual Report Analysis FY2024
Highlights
Business Overview
Medtronic plc is a global healthcare technology company that develops, manufactures, and sells medical devices and services, including implantable cardiac devices, ablation systems, and diabetes management solutions (10-K). The company operates four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit (10-K). Key competitive advantages include a robust R&D pipeline ($2.7B in R&D expenses) (XBRL), innovative technologies (e.g., AI, remote monitoring), and a diversified product portfolio (10-K). The company serves healthcare systems, physicians, clinicians, and patients across 150+ countries, with no significant customer concentration (10-K).
Revenue Analysis
Revenue increased 5.2% YoY to $31.7B (XBRL), with historical growth showing a 5-year CAGR of +0.8% (XBRL). Operating income rose 28.3% YoY to $5.8B (XBRL), outpacing the 5-year CAGR of -3.7% (XBRL) for operating income. Net income surged 39.7% YoY to $5.0B (XBRL), with a 5-year CAGR of +3.9% (XBRL). Growth drivers include innovation in medical devices, strong financial health (56.6% equity ratio) (XBRL), and strategic focus on high-margin segments.
Profitability Analysis
Operating margin improved to 18.1% (XBRL), while net margin reached 15.9% (XBRL). EBITDA of $8.5B (26.7% of revenue) (XBRL) reflects strong cost control and operational efficiency. Net income grew 39.7% YoY (XBRL), with a 5-year CAGR of +3.9% (XBRL), outperforming operating income's 5-year CAGR of -3.7% (XBRL).
Balance Sheet Analysis
Total assets declined slightly to $90.9B (XBRL) in FY2024, while total equity fell to $51.5B (XBRL). The company maintains a strong equity ratio of 56.6% (XBRL) and a conservative debt-to-equity ratio of 0.76x (XBRL). Liquidity is robust, with a current ratio of 2.39x (XBRL) and $1.5B in cash (XBRL).
Cash Flow Analysis
Operating cash flow increased to $7.3B (XBRL), with free cash flow of $6.0B (XBRL) after $1.4B in CapEx (XBRL). Financing activities included $3.4B in dividends (XBRL) and $2.5B in share repurchases (XBRL), totaling $5.9B in shareholder returns (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 164 days (XBRL), with receivables days at 69 days (XBRL), inventory days at 190 days (XBRL), and payables days at 96 days (XBRL). Asset turnover of 0.35x (XBRL) suggests underutilization of assets.
Risks
Outlook
The 10-K does not provide specific management guidance for FY2025. However, the company's R&D investment ($2.7B) (XBRL) and strong financial position (56.6% equity ratio) (XBRL) may support future growth despite challenges in reimbursement and competition.
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 30.0B | 30.6B | 28.9B | 30.1B | 31.7B | 31.2B |
| Operating Income | 6.6B | 6.3B | 4.8B | 4.5B | 5.8B | 5.5B |
| Net Income | 3.1B | 4.6B | 4.8B | 3.6B | 5.0B | 3.8B |
| Total Assets | 89.7B | 90.7B | 93.1B | 91.0B | 90.9B | 90.0B |
| Total Equity | 50.1B | 50.7B | 51.4B | 52.6B | 51.5B | 50.2B |
| Operating Cash Flow | 4.7B | 7.0B | 7.2B | 6.2B | 7.3B | 6.0B |
Health Careの企業一覧
Medtronic plcと同じ「Health Care」セクターの企業